44. Wegener granulomatosis
84 clinical trials,   88 drugs   (DrugBank: 22 drugs),   13 drug target genes,   37 drug target pathways

Searched query = "Wegener granulomatosis", "Multiple vasculitis granulomatous disease", "Granulomatosis with polyangiitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 0 mg Prednisone; 0 mg prednisone; 5 mg Prednisone; 5 mg prednisone; ABATACEPT; AZD7986; Abatacept; Abatacept (CTLA4-Ig); Alemtuzumab; Avacopan; Azathioprin-ratiopharm® 25 mg Filmtabletten; Azathioprine; Azathioprine 25 mg; Belimumab; Benralizumab; Biological: Benralizumab, Biological: Placebo to Mepolizumab; Biological: Mepolizumab, Biological: Placebo to Benralizumab; Blisibimod; CCX168; CYCLOPHOSPHAMIDE; Chimeric monoclonal antibody, IgG4 subtype; Corticosteroid; Corticosteroid and azathioprine; Cyclophosphamide; Cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids; Cyclophosphamidum; Cyclophosphamidum 500 mg; Endoxan; Endoxan® 500 mg; GALEN® tablet; Glucocorticoid (GC); Glucocorticoids; Glucocorticoids (GC); Glucocorticoids - Reduced Dose; Glucocorticoids - Standard Dose; Glucocorticoids [Reduced Dose]; Glucocorticoids [Standard Dose]; Gusperimus; Gusperimus + glucocorticoids; Hydroxychloroquine; IFX-1; INS1007; L04AC06; MEDI-563; MEPOLIZUMAB; MESNA; METOJECT 10 mg/ml, solution injectable en seringue pré-remplie; MabThera; MabThera®; Mepolizumab; Mesna; Metex 2,5 mg Tabletten; Methotrexate; Methotrexate 2.5 mg; Methotrexate 25 mg; NUCALA; Naltrexone; Naltrexone Hydrochloride; Nucala; Nucala 100 mg powder for solution for injection; Orencia; Other: No Plasma Exchange; PREDNISONE; Pednisone; Plaquenil - Hydroxychloroquine 200mg Film coated tablets; PredniSONE Tablets, USP; Prednisolone; Prednison acis® 20 mg; Prednison acis® 5 mg; Prednisone; Procedure: Plasma Exchange; RITUXIMAB; RO0452294/V01; RO0452294/V02; Recombinant humanized monoclonal antibody specific for human IL-5; Remission induction therapy; Reslizumab; Rituximab; Rituximab (Arm A); Rituximab (Arm B); SB-240563; SB-240563 (mepolizumab); Sulfamethoxazole; Trimethoprim; Trimethoprim Sulfamethoxazole; Vitamin D; Yellow Fever Vaccine; Yellow Fever vaccine (17D)